Skye Bioscience (SKYE) EBT Margin (2013 - 2014)
Skye Bioscience's (SKYE) quarterly EBT Margin came in at 9.92% in Q2 2014, down 1279.0% year-over-year from 0.84% in Q2 2013, and down 49.18% quarter-over-quarter from 6.65% in Q4 2013.
Powered by 
Analysis
Skye Bioscience (SKYE) EBT Margin (2013 - 2014) Analysis & Trends
Skye Bioscience (SKYE) has reported EBT Margin for 2 consecutive years, with 9.92% the latest figure, recorded in Q2 2014.
- On a quarterly basis, EBT Margin fell 1279.0% year-over-year to 9.92% in Q2 2014; TTM through Apr 2014 was 33.16%, a N/A change from a year earlier, with the FY2013 full-year figure at 1.11%, down 3039.0% from the prior year.
- EBT Margin was 9.92% for Q2 2014 at Skye Bioscience, down from 6.65% in the prior quarter.
- Over five years, EBT Margin peaked at 2.87% in Q2 2013 and troughed at 9.92% in Q2 2014.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 27.53% |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -131.41% |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 41.75% |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 35.61% |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 35.78% |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | -528.97% |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 13.77% |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 4.84% |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | -20,427.46% |
| 10 | Skye Bioscience | 11.01 Mn | 11.01 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Apr 30, 2014 | -9.92% |
| Oct 31, 2013 | -6.65% |
| Jul 31, 2013 | -1.65% |
| Apr 30, 2013 | 2.87% |
| Jan 31, 2013 | 0.42% |